Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regenerationUniversity of California San Diego and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers described in Cell Stem Cell an IRF4 antisense oligonucleotide (ASO), ION251, that reduced tumor growth, impaired myeloma progenitor regeneration and...

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...

The Phase III miss for Merck KGaA’s bintrafusp alfa in non-small cell lung cancer takes one of the most promising indications for the GSK-partnered program out of contention, and raises questions about...

The debut of two more venture-backed companies developing early cancer detection tests suggests there is still appetite for new approaches, even as bigger players consolidate via M&A and prepare for commercial launch. Delfi Diagnostics Inc....

After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc. as CFO on Jan. 25. Frates said he felt a “calling” to do more to combat amyotrophic lateral sclerosis after his cousin...

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....

In its first deal with a major pharma, ArsenalBio will put its synthetic biology toolkit to the test in creating programmable T cell therapies against solid tumor targets chosen by BMS. ArsenalBio as among the...